A generic alternative indicated for Oncology Support. Facilitates the targeted management of specific cancer cells to support cellular balance and patient well-being.
Utilized to manage specific leukemia types by addressing abnormal cell proteins to alleviate cancer progression and support improved clinical survival outcomes in patients.
Mechanism of Action
Dasatinib blocks BCR-ABL and other tyrosine kinases. These are proteins that act as 'on switches' for cancer cells to grow. By turning them off, it stops the rapid production of abnormal white blood cells.
Route of Administration
Oral
Onset Time
Steady state in 1 week
Duration
24 hours
Contraindications
Hypersensitivity to dasatinib, Pregnancy
Severe Adverse Events
Pulmonary arterial hypertension, Severe fluid retention, Congestive heart failure, Severe bleeding, Severe skin reactions, Liver toxicity
Information for Dasatinib is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
